Latest From Humanigen Inc.
Tech Transfer Roundup: Anixa Thinks Cleveland Clinic IP Offers Potential In Triple-Negative Breast Cancer
Anixa obtains cancer vaccine targeted to proteins common in breast cancer from Cleveland Clinic. Arxx licenses Cancer Research UK antibody that targets tumor microenvironment.
Appointments: Celgene, Hikma Pharmaceuticals, Silence Therapeutics, Sosei, BioNTech, Nordic Nanovector And Axcella Health Announce New Hires
Companies announcing executives moves this week include Celgene with a new CFO, Hikma Pharmaceuticals, Silence Therapeutics, Sosei, BioNTech, Nordic Nanovector, Axcella Health, and NDA Group. The British Generic Manufacturers Association also announced a new chair.
Norwegian biotech is starting PARADIGME Phase IIb trial testing Betalutin in follicular lymphoma.
Irish biotech focused on Endobody vaccine candidates partners with Boston U. in CTE and U. of Texas in Alzheimer’s. Lupus Research Alliance affiliate will help Bristol conduct a Phase II trial of Tyk2 inhibitor in lupus.
- Large Molecule
- Therapeutic Areas
- KaloBios Pharmaceuticals Inc.
- North America
- Parent & Subsidiaries
- Humanigen Inc.
- Senior Management
Cameron Durrant, MD, CEO
Greg Jester, CFO
Niv Caviar, Head, Corp. & Bus. Dev.
Morgan Lam, CSO
- Contact Info
1000 Marina Blvd.
Brisbane, CA 94005
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.